
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Munc13-4 CRISPR Activation Plasmid (h) | sc-404319-ACT | 20 µg | $397.00 |
UNC13D encodes Munc13-4, a priming factor essential for Ca²⁺-regulated exocytosis of cytotoxic granules and other secretory lysosomes in immune cells. Munc13-4 coordinates vesicle docking and fusion by regulating SNARE complex assembly, supporting pathways that control degranulation, membrane trafficking, and regulated secretion. Altered UNC13D function disrupts cytolytic activity of NK cells and cytotoxic T lymphocytes and is associated with immune dysregulation syndromes characterized by impaired granule release. As a result, UNC13D is frequently studied in the context of lymphocyte effector function, vesicular transport checkpoints, and inflammatory signaling linked to defective secretion.
Munc13-4 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous UNC13D expression without altering the underlying DNA sequence.
Munc13-4 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the UNC13D locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the UNC13D transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Munc13-4 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native UNC13D locus and enabling the study of Munc13-4-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Munc13-4 pathway restoration in tumor cells with silenced or reduced UNC13D expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.